A Phase I Study of NKTR-255 in People with Multiple Myeloma or Non-Hodgkin Lymphoma

Share
Print

Full Title

A Phase 1, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 in Relapsed or Refractory Hematological Malignancies

Purpose

The purpose of this study is to find the highest dose of the investigational drug NKTR-255 that can be given safely in patients with multiple myeloma or non-Hodgkin lymphoma that has come back or continued to grow despite prior treatment. NKTR-255 was developed in a laboratory as a form of IL-15 (interleukin-15), a protein made by the immune system that activates an immune response against cancer cells. It is given intravenously (by vein).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have multiple myeloma or non-Hodgkin lymphoma that came back or continued to grow despite prior treatment.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 to 80.

For more information about this study and to inquire about eligibility, please contact Dr. Miguel-Angel Perales at 212-639-8682.

Protocol

20-465

Phase

I

Disease Status

Relapsed or Refractory

Investigator

Co-Investigators